Navigation Links
Gene may hold key to future cancer hope
Date:10/8/2007

Scientists may have discovered a new way of killing tumours in what they hope could one day lead to alternative forms of cancer treatments.

The University of Manchester research has identified a key gene that appears to play a critical role in the normal process of cell division.

Cells divide creating new cells as part of the bodys natural growth, renewal and healing processes but cancer results when cells divide in an uncontrolled way.

What the Manchester team has discovered is that a protein in our cells called Bub 1 is essential for normal cell division to take place; if the gene that generates Bub 1 is switched off then the cells are unable to divide successfully.

Bub 1 is an enzyme that controls several processes required for cell division to occur, said Dr Stephen Taylor, who led the research in the Faculty of Life Sciences.

We have shown that mouse embryos lacking the Bub 1 gene are unable to develop. Older cell types also failed to divide when the gene is switched off, while male mice lacking Bub 1 became infertile as their sperm cells died.

In fact, deactivating Bub 1 had such a profound effect on cell division at all stages of a cells life - known as the cell cycle - that the team is hopeful it will have a similar effect on cancer cells.

Before cells can divide they have to duplicate and then distribute their genetic material so that the two daughter cells receive all the genetic information for further growth and development, said Dr Taylor, whose work is funded by the charity Cancer Research UK.

The distribution phase has to be done with a high degree of accuracy - just one chromosome segregated incorrectly, for instance, leads to Downs syndrome - so the cell has a surveillance mechanism which acts as a brake to delay chromosome segregation until accuracy has been guaranteed.

An important part of this intricate surveillance system is Bub 1. The team found that when the gene is switched off the surveillance mechanism fails and accuracy is lost, resulting in cell death.

Now that scientists understand the precise role of Bub 1 in normal cell division, as well as what goes wrong when the gene is missing, they plan to test their theory on cancer cells.

Unlike some other genes that become mutated in cancer cells, the Bub 1 gene appears normal indicating that it behaves in exactly the same way in cancer cells as it does in healthy cells.

If this is the case, then we can be confident that switching it off will stop cancer cells proliferating too. And while our normal cells dont divide that often, cancer cells divide more frequently, so hopefully by targeting Bub1 we will selectively kill cancer cells.

Equally exciting, says Dr Taylor, is the fact that drugs are already being developed that are able to block the actions of Bub 1-type enzymes, known as protein kinases; such kinase blockers or inhibitors are already providing a whole new approach to tackling cancer and Bub1 inhibitors may be another weapon in the oncologist's arsenal.

The research, which began in 1999, is published in the journal Developmental Cell on Tuesday, October 9.


'/>"/>
Contact: Aeron Haworth
aeron.haworth@hotmail.com
44-161-275-8383
University of Manchester
Source:Eurekalert

Related biology news :

1. HIV vaccine trial breaks ground for future research
2. Future diabetes drugs may target new protein interaction
3. Prozac for future Plants on Mars
4. Purdues gold nanorods brighten future for medical imaging
5. Plants reveal a secret and bring researchers nearer a cleaner future
6. Report focuses on challenges to unlocking future promise of vaccines
7. Researchers make long DNA wires for future medical and electronic devices
8. New U. of Colorado at Boulder flu chip may help combat future epidemics, pandemics
9. Understanding the oceans microbes is key to the Earths future
10. Tastier tomatoes in the future?
11. Stable polymer nanotubes may have a biotech future
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/6/2017)... 2017 Forecasts by Product Type ... by End-Use (Transportation & Logistics, Government & Public Sector, ... Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation ... Are you looking for a definitive report on the ... ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/28/2017)... , March 28, 2017 ... Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video ... and Region - Global Forecast to 2022", published by ... in 2016 and is projected to reach USD 75.64 ... 2017 and 2022. The base year considered for the ...
Breaking Biology News(10 mins):
(Date:8/17/2017)... Village, CA (PRWEB) , ... August 17, 2017 ... ... technology for cancer research and personalized medicine, today announced the launch of a ... Kansas City, Missouri. The study’s goal is to evaluate the potential for early ...
(Date:8/16/2017)... ... 2017 , ... Today, 3Bar Biologics Inc ., the ... funding from an impressive group of investors, including Rev1 Ventures, Maumee Ventures, Ohio ... investment, 3Bar is broadening availability of its groundbreaking offering that uses naturally occurring ...
(Date:8/15/2017)... NC (PRWEB) , ... August 15, 2017 , ... ... 2017, celebrating 10 years of successes helping medical technology companies and inventors develop and ... to a renowned full-service national engineering firm with a portfolio of clients in the ...
(Date:8/15/2017)... , ... August 15, 2017 , ... The Conference ... on Immuno-Oncology 360° (IO360°) programming through a series of upcoming panels and events. The ... 7-9, 2018, at The Roosevelt Hotel in New York City. , “With our experience ...
Breaking Biology Technology: